Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
Journal of Psychopharmacology April 1, 2024 Nelson B Rodrigues, David C J Chen-Li, Joshua D. Di Vincenzo et al. 12 citations
Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine's biochemistry as reliable predictors of response. No studies have...
DOI: 10.1177/02698811241238284 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Treatment-resistant depression
Pharmacogenetics
Tolerability
+3